116 completed, 23 unknown, 18 terminated, 10 recruiting. 51 Phase 3, 45 Phase 2, 37 Phase 4, 31 Not applicable, 18 Phase 1.
Follow Fenofibrate: new trials by email Literature Review of Fenofibrate trials Research Report on Fenofibrate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison Of Fenofibrate Vs Phenobarbitone As Adjunct To Phototherapy In Reducing Total Serum Bilirubin In Indirect Hyperbilirubinemia In Neonates Fenofibrate + Phototherapy, Phenobarbitone + Phototherapy - Jaundice, Neonatal | Phase 4 | Not yet recruiting | Rubab Fatima | 70 | 2026-10-01 | 2026-08-19 |
| Clinical Study Evaluating the Efficacy and Safety of Fenofibrates Versus Silymarin in Adult Patients With Sepsis Fenofibrate, Silymarin - Sepsis | Phase 2 | Not yet recruiting | Tanta University | 66 | 2026-05-01 | 2026-05-07 |
| FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy Fenofibrate, UDCA (Ursodeoxycholic acid) - Primary Biliary Cholangitis (PBC) | Phase 3 | Recruiting | Xijing Hospital of Digestive Diseases | 132 | 2025-12-15 | 2025-12-29 |
| Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM) Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg tablet, Bortezomib + Lenalidomide + Dexamethasone - Peripheral Neuropathy, Multiple Myeloma, Neoplasms | Phase 4 | Recruiting | Tanta University | 44 | 2025-08-30 | 2025-11-04 |
| Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia Atorvastatin, Simvastatin, Rozuvastatin - Atherosclerotic Cardiovascular Disease | Recruiting | Novartis Pharmaceuticals | 2382 | 2025-04-15 | 2025-08-03 | |
| Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation Fenofibrate (drug), Blood draw for the laboratory assessment, MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA) - Primary Sclerosing Cholangitis, Liver Transplant, Complications | Phase 2 | Recruiting | Mayo Clinic | 80 | 2025-04-15 | 2026-07-17 |
| Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC) Fenofibrate - Primary Biliary Cholangitis (PBC) | Early Phase 1 | Active not recruiting | Xijing Hospital of Digestive Diseases | 15 | 2025-03-13 | 2026-07-29 |
| Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma Fenofibrate, Cervical Conization, Hysterectomy - Cervical Intraepithelial Neoplasia, Invasive Cervical Cancer | Phase 1 | Recruiting | Lindsay Ferguson, MD | 24 | 2024-11-20 | 2026-07-27 |
| A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis Fenofibrate, UDCA (Ursodeoxycholic acid) - Primary Biliary Cholangitis (PBC) | Early Phase 1 | Completed | Han Ying | 30 | 2024-09-14 | 2026-08-05 |
| Comparison of Effects of Fenofibrate Adjuvant Therapy Versus Conventional Phototherapy in Neonatal Jaundice. Fenofibrate, Phototherapy - Physiological Neonatal Jaundice, Physiological Hyperbilirubinaemia | Phase 2 / Phase 3 | Unknown | Muhammad Zark | 156 | 2024-04-01 | 2024-04-04 |
| To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin, Dose escalation of moderate-intensity statin - T2DM (Type 2 Diabetes Mellitus), Dyslipidemias | Not applicable | Recruiting | Korea University Anam Hospital | 3958 | 2024-03-01 | 2024-08-27 |
| Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study Fenofibrate in Combination With Ursodeoxycholic Acid - Primary Biliary Cholangitis (PBC) | Phase 3 | Recruiting | Xijing Hospital of Digestive Diseases | 150 | 2024-01-30 | 2026-01-08 |
| Fenofibrate in Primary Biliary Cholangitis: a Real World Study Fenofibrate - Primary Biliary Cholangitis (PBC) | Phase 3 | Recruiting | Xijing Hospital of Digestive Diseases | 300 | 2024-01-17 | 2026-01-08 |
| Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients Fenofibrate, Placebo, Doxorubicin - Breast Cancer Stage 2 and 3 | Phase 2 | Completed | Tanta University | 44 | 2023-12-01 | 2025-08-19 |
| Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis Fenofibrate, Placebo, UDCA - Primary Biliary Cholangitis | Phase 2 / Phase 3 | Active not recruiting | Han Ying | 184 | 2023-08-21 | 2026-08-20 |
| Role of Fenofibrate in Neonatal Jaundice Fenofibrate, placebo - Neonatal Jaundice | Phase 4 | Completed | Ain Shams University | 75 | 2023-07-01 | 2024-06-11 |
| Repurposing Fenofibrate in Modulating AMPK/NLRP3 Inflammasome in Patients With Ulcerative Colitis Mesalamine, Fenofibrate - Inflammatory Bowel Diseases | Phase 2 | Completed | Tanta University | 70 | 2023-03-20 | 2026-10-13 |
| Fenofibrate in Ulcerative Colitis Mesalamine, Fenofibrate 160mg - Inflammatory Bowel Diseases | Phase 2 / Phase 3 | Completed | Tanta University | 60 | 2023-02-28 | 2026-05-04 |
| Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis Fenofibrate 200mg, Placebo, UDCA - Primary Biliary Cholangitis | Phase 2 / Phase 3 | Recruiting | Xijing Hospital of Digestive Diseases | 104 | 2023-02-17 | 2026-01-08 |
| Fenofibrate Role in Breast Cancer Patients Placebo, Fenofibrate 160mg - Breast Cancer | Not applicable | Completed | Damanhour University | 50 | 2023-01-01 | 2025-07-08 |
Showing 20 of 181. Sign in to see all of them.
Dyslipidemias (34) · Hypertriglyceridemia (26) · Hyperlipidemias (18) · Diabetes Mellitus (15) · Diabetes Mellitus, Type 2 (15) · Insulin Resistance (14) · Cardiovascular Diseases (13) · Liver Cirrhosis, Biliary (12) · Metabolic Syndrome (11) · Hypercholesterolemia (9) · Obesity (8) · Diabetic Retinopathy (7) · Non-alcoholic Fatty Liver Disease (6) · Burns (4) · Coronary Disease (4)
Solvay Pharmaceuticals (17) · Xijing Hospital of Digestive Diseases (8) · Abbott (7) · Sanofi (6) · Tanta University (5) · Chong Kun Dang Pharmaceutical (4) · Gachon University Gil Medical Center (4) · Ranbaxy Laboratories Limited (4) · University of Pennsylvania (4) · GlaxoSmithKline (3) · Mutual Pharmaceutical Company, Inc. (3) · Pfizer (3) · The University of Texas Medical Branch, Galveston (3) · University of Miami (3) · VA Office of Research and Development (3)
United States (72) · China (16) · Canada (14) · France (12) · Poland (12) · Russia (11) · South Korea (11) · Czechia (9) · Germany (9) · United Kingdom (9) · Egypt (8) · Finland (8) · Hungary (8) · Italy (8) · Ukraine (7)
Cynthia Levy, MD (2) · David N Herndon, MD (2) · Agnieszka Szypowska, MD, PhD,Prof (1) · Alessandro Doria, MD PhD MPH (1) · Alicia Jenkins, Professor (1) · Anthony Keech, Professor (1) · Anthony R Godfrey, Pharm. D. (1) · Anthony R Godfrey, Pharm.D. (1) · Ashok Balasubramanyam, MD (1)
PMID 17245174, PMID 20587587, PMID 21518985, PMID 24360972, PMID 24740208, PMID 25172198, PMID 27289122, PMID 16218799, PMID 16843192, PMID 17434848, PMID 17971707, PMID 18539917, PMID 18783301, PMID 19116237, PMID 19331437, PMID 19597368, PMID 19651918, PMID 19820283, PMID 19898642, PMID 20061358, PMID 20061360, PMID 20110022, PMID 20212201, PMID 20215456, PMID 20228401, PMID 20228404, PMID 20297950, PMID 20427682, PMID 20571135, PMID 20594588, PMID 20824151, PMID 20934572, PMID 21366473, PMID 21565796, PMID 21663644, PMID 21958949, PMID 22019270, PMID 22049171, PMID 22179956, PMID 22263674, PMID 22374637, PMID 22432114, PMID 22450889, PMID 22515638, PMID 22619083, PMID 22646230, PMID 22709833, PMID 22723577, PMID 23033246, PMID 23130172
2005 (5), 2004 (2), 2015 (2), 2017 (2), N01HC095178 (1), N01HC95178 (1), N01HC95179 (1), N01HC95180 (1), N01HC95181 (1), N01HC95182 (1), N01HC95183 (1), N01HC95184 (1), P20HL113444 (1), P30CA006516 (1), P50HL083799 (1)